Patents by Inventor Shaun M. Lippow

Shaun M. Lippow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bi-Specific Fusion Proteins
    Publication number: 20240101713
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: October 9, 2023
    Publication date: March 28, 2024
    Applicant: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • ANTIBODIES TO CORONAVIRUS SARS-COV-2
    Publication number: 20240025971
    Abstract: Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.
    Type: Application
    Filed: October 22, 2021
    Publication date: January 25, 2024
    Inventors: Katherine L. WILLIAMS, Daniel Eric EMERLING, Shaun M. LIPPOW, Ngan Nguyen ATKINS
  • ANTIBODY SCAFFOLD STRUCTURE
    Publication number: 20230381130
    Abstract: Provided herein are antibodies comprising a scaffold region and methods of using such antibodies to generate antibodies with binding specificities that differ from a parent antibody that comprises the scaffold region.
    Type: Application
    Filed: April 13, 2023
    Publication date: November 30, 2023
    Inventors: Jessica FINN, Shaun M. LIPPOW
  • Bi-specific fusion proteins
    Patent number: 11814443
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: November 14, 2023
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • ANTI-CSP ANTIBODIES
    Publication number: 20230167169
    Abstract: The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions comprising such antibodies. Also disclosed are methods of producing the disclosed antibodies and methods of treating or preventing malaria using the same.
    Type: Application
    Filed: January 26, 2023
    Publication date: June 1, 2023
    Applicant: Atreca, Inc.
    Inventors: Daniel Eric Emerling, Randal R. Ketchem, Shaun M. Lippow, Wayne Volkmuth, Katherine L. Williams
  • Anti-CSP antibodies
    Patent number: 11655290
    Abstract: The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions comprising such antibodies. Also disclosed are methods of producing the disclosed antibodies and methods of treating or preventing malaria using the same.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: May 23, 2023
    Assignee: Atreca, Inc.
    Inventors: Daniel Eric Emerling, Randal R. Ketchem, Shaun M. Lippow, Wayne Volkmuth, Katherine L. Williams
  • ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND THERAPY
    Publication number: 20230140035
    Abstract: Provided herein are antibodies that bind to tumor tissue through a binding interaction with an extracellular RNA-protein complex. Such antibodies are used in methods of inducing an immune response and methods of inhibiting tumor cell growth. Additionally provided are methods of producing such antibodies.
    Type: Application
    Filed: September 26, 2022
    Publication date: May 4, 2023
    Inventors: Jeff DeFalco, Daniel Eric Emerling, Jessica Finn, Norman Michael Greenberg, Vera Huang, Shaun M. Lippow, Fengling Liu, Amy Manning-Bog, William H. Robinson, Alexander Scholz, Tito Serafini, Nikhil Vad, Wayne Volkmuth, Yann Chong TAN
  • ANTI-CSP ANTIBODIES
    Publication number: 20230002483
    Abstract: The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions comprising such antibodies. Also disclosed are methods of producing the disclosed antibodies and methods of treating or preventing malaria using the same.
    Type: Application
    Filed: June 16, 2022
    Publication date: January 5, 2023
    Applicant: Atreca, Inc.
    Inventors: Daniel Eric Emerling, Randal R. Ketchem, Shaun M. Lippow, Wayne Volkmuth, Katherine L. Williams
  • Antibodies that bind tumor tissue for diagnosis and therapy
    Patent number: 11472885
    Abstract: Provided herein are antibodies that bind to tumor tissue through a binding interaction with an extracellular RNA-protein complex. Such antibodies are used in methods of inducing an immune response and methods of inhibiting tumor cell growth. Additionally provided are methods of producing such antibodies.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: October 18, 2022
    Assignee: Atreca, Inc.
    Inventors: Jeff DeFalco, Daniel Eric Emerling, Jessica Finn, Norman Michael Greenberg, Vera Huang, Shaun M. Lippow, Fengling Liu, Amy Manning-Bog, William H. Robinson, Alexander Scholz, Tito Serafini, Yann Chong Tan, Nikhil Vad, Wayne Volkmuth
  • EPHA2 ANTIBODIES
    Publication number: 20220306752
    Abstract: Provided herein are EphA2 antibodies. These EphA2 antibodies bind preferentially to tumor tissue than normal tissue and bind to EphA2. Such antibodies are used in methods of inducing an immune response and methods of inhibiting tumor cell growth. Additionally provided are methods of producing such antibodies.
    Type: Application
    Filed: March 4, 2022
    Publication date: September 29, 2022
    Inventors: Alexander SCHOLZ, Nikhil VAD, Michael Samuel WEISS, Anne YE, Danhui ZHANG, Iraz T. AYDIN, Maryam M. BHATTI, Sean CARROLL, Jessica FINN, Shuning GAI, Shaun M. LIPPOW, Amy MANNING-BOG, Philippe MARGUET
  • ANTI-CSP ANTIBODY VARIANTS
    Publication number: 20220195023
    Abstract: Provided herein are anti-circumsporozoite (CSP) antibodies, compositions comprising such antibodies, and methods of producing the antibodies. Additionally provided are methods of treating or preventing malaria using the anti-CSP antibodies.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 23, 2022
    Inventor: Shaun M. Lippow
  • Bi-Specific Fusion Proteins
    Publication number: 20210214463
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 15, 2021
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-specific fusion proteins
    Patent number: 10988547
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: April 27, 2021
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • ANTI-HIV ANTIBODIES
    Publication number: 20210040184
    Abstract: Provided herein are anti-HIV antibodies, compositions comprising such antibodies, and methods of producing the antibodies. Additionally provided are methods of treating or preventing HIV infection, or a complication of HIV infection, using the anti-HIV antibodies.
    Type: Application
    Filed: September 9, 2020
    Publication date: February 11, 2021
    Inventors: Guy L. CAVET, Anthony Devico, Dongkyoon Kim, George K. Lewis, Shaun M. Lippow, Mohammad Sajadi, Katherine Williams
  • ANTI-HIV ANTIBODIES
    Publication number: 20210040185
    Abstract: Provided herein are anti-HIV antibodies, compositions comprising such antibodies, and methods of producing the antibodies. Additionally provided are methods of treating or preventing HIV infection, or a complication of HIV infection, using the anti-HIV antibodies.
    Type: Application
    Filed: September 9, 2020
    Publication date: February 11, 2021
    Inventors: Guy L. CAVET, Anthony Devico, Dongkyoon Kim, George K. Lewis, Shaun M. Lippow, Mohammad Sajadi
  • ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS AND THERAPY
    Publication number: 20200325242
    Abstract: Provided herein are antibodies that bind to tumor tissue through a binding interaction with an extracellular RNA-protein complex. Such antibodies are used in methods of inducing an immune response and methods of inhibiting tumor cell growth. Additionally provided are methods of producing such antibodies.
    Type: Application
    Filed: February 14, 2020
    Publication date: October 15, 2020
    Inventors: Jeff DeFalco, Daniel Eric Emerling, Jessica Finn, Norman Michael Greenberg, Vera Huang, Shaun M. Lippow, Fengling Liu, Amy Manning-Bog, William H. Robinson, Alexander Scholz, Tito Serafini, Yann Chong Tan, Nikhil Vad, Wayne Volkmuth
  • Bi-Specific Fusion Proteins
    Publication number: 20200048368
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: July 29, 2019
    Publication date: February 13, 2020
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-specific fusion proteins
    Patent number: 10407512
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 10, 2019
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Engineered Nucleases and Their Uses for Nucleic Acid Assembly
    Publication number: 20190112586
    Abstract: Aspects of the invention provide engineered endonucleases that are characterized by both a long recognition sequence and specific cleavage outside of the recognition site. Engineered endonucleases of the invention are useful for manipulating long pieces of DNA.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 18, 2019
    Inventors: Shaun M. Lippow, Dasa Lipovsek, Patricia M. Aha
  • Bi-Specific Fusion Proteins
    Publication number: 20170335015
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: June 9, 2017
    Publication date: November 23, 2017
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow